CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis - 03/12/18
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 13 |
| Iconographies | 7 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
Associations between CDKN2A promoter methylation and HCC were reported with controversies, but confirmed in our study with further associations between the methylation and expression, virus infection, cirrhosis status and age. The methylation in blood could be a potential HCC marker.
Le texte complet de cet article est disponible en PDF.Summary |
Aim |
Lots of studies have explored cyclin-dependent kinase inhibitor 2A (CDKN2A) promoter methylation in hepatocellular carcinoma (HCC), but the established results were controversial. Hence, we conducted the meta-analysis to comprehensively investigate the association between CDKN2A promoter methylation and HCC risk.
Methods |
A comprehensive search was implemented through searching PubMed, Web of Science and Embase. Associations of CDKN2A promoter methylation with HCC risk, clinicopathological features, and CDKN2A expression were assessed by the pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Subgroup analyses and meta-regression were served for exploring the potential sources of heterogeneity.
Results |
A total of 59 articles including 3067 cases and 2951 controls were incorporated in this meta-analysis. Overall, we observed a high CDKN2A promoter methylation rate (58.18%) in HCC and a significant association between the methylation and HCC risk (OR, 7.07; 95% CI, 5.67–8.80). Furthermore, CDKN2A promoter methylation was robustly associated with decreased mRNA (OR, 13.89; 95% CI, 5.44–35.45) and protein (OR, 48.19; 95% CI, 5.56–417.29). In addition, we found the methylation was related with HBV infection (OR, 3.31; 95% CI, 1.47–7.47), HCV infection (OR, 2.76; 95% CI, 1.80–4.23), cirrhosis status (OR, 1.57; 95% CI, 1.01–2.44) and older age (OR, 1.83; 95% CI, 1.14–2.94).
Conclusions |
Our results indicated that CDKN2A promoter methylation was associated with an enhancive HCC risk and played a crucial role in the process of HCC with a potential value to being a triage marker for HCC.
Le texte complet de cet article est disponible en PDF.Keywords : Methylation, CDKN2A, Hepatocellular carcinoma, Meta-analysis
Abbreviations : CDKN2A, HCC, CIs, ORs, S-ROC, MSP, BSP, Q-MSP, MSRE-qPCR, HSCs, HBV, HCV
Plan
Vol 42 - N° 6
P. 529-541 - décembre 2018 Retour au numéro
Article précédent
- Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French–Spanish experience
- Sara Lemoinne, Albert Pares, Anna Reig, Karima Ben Belkacem, Astrid Donald Kemgang Fankem, Farid Gaouar, Raoul Poupon, Chantal Housset, Christophe Corpechot, Olivier Chazouillères
- Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma: Five-year retrospective study
- Yi-Sheng Liu, Chia-Ying Lin, Ming-Tsung Chuang, Yi-Shan Tsai, Chien-Kuo Wang, Ming-Ching Ou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?